Compare PAGP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAGP | ERAS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.0B |
| IPO Year | 2013 | 2021 |
| Metric | PAGP | ERAS |
|---|---|---|
| Price | $24.37 | $14.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $22.11 | $14.25 |
| AVG Volume (30 Days) | 1.7M | ★ 4.8M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | ★ 370.00 | 36.23 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $44,262,000,000.00 | N/A |
| Revenue This Year | $10.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $90.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.69 | $1.24 |
| 52 Week High | $26.15 | $24.28 |
| Indicator | PAGP | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 58.30 |
| Support Level | $24.26 | $14.00 |
| Resistance Level | $24.63 | $15.58 |
| Average True Range (ATR) | 0.44 | 1.09 |
| MACD | -0.11 | 0.31 |
| Stochastic Oscillator | 6.93 | 77.32 |
Plains GP Holdings LP owns and operates midstream energy infrastructure and provides logistics services for crude oil, natural gas liquids (NGL), and natural gas. The group manages its operations through two operating segments: Crude Oil segment operations generally consist of gathering and transporting crude oil using pipelines (including gathering systems), trucks, and, at times, on barges or railcars; and NGL segment operations involve NGL storage and terminalling from NGL assets located in the Southwestern United States. It generates the majority of its revenue from the Crude Oil segment. Its geographic markets are the United States and Canada. It generates the majority of its revenue from the United States.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.